UBS O'Connor’s Aldeyra Therapeutics ALDX Stock Holding History

UBS O'Connor’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-92,500	Closed	-$487K	–	320
2019 Q3	$487K	Buy	+92,500	New	+$498K	0.01%	240

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

UBS O'Connor's ALDX Position: Q4 2019 in Review

UBS O'Connor sold out of Aldeyra Therapeutics (ALDX) in Q4 2019, closing a stake of 92,500 shares — an estimated $487K sold.

UBS O'Connor first reported a position in ALDX in Q3 2019 and held it in 1 quarter. The position peaked at $487K in Q3 2019. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2019.

UBS O'Connor reported no remaining Aldeyra Therapeutics position as of Q4 2019 after selling out during the quarter.
UBS O'Connor sold 92,500 Aldeyra Therapeutics shares in Q4 2019, an estimated $487K.
UBS O'Connor first reported a position in Aldeyra Therapeutics in Q3 2019 and held it in 1 quarter.
UBS O'Connor's Aldeyra Therapeutics position peaked at $487K in Q3 2019.
77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2019.

Based on UBS O'Connor's 13F filing for Q4 2019, filed 14 Feb 2020.